<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of fatty acid oxidation disorders</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of fatty acid oxidation disorders</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of fatty acid oxidation disorders</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Enzyme</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Prevalence</td> <td class="subtitle1">Symptoms</td> <td class="subtitle1">Other complications</td> <td class="subtitle1">Plasma acylcarnitines</td> </tr> <tr> <td>VLCADD</td> <td>Very long-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADVL</em></td> <td>1 in 42,500 to 120,000</td> <td>G, L, C, M, R</td> <td> </td> <td>Elevated C14:1–, C14–, C16:1–, C16–</td> </tr> <tr> <td>LCHADD</td> <td>Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td> <td><em>HADHA</em></td> <td>1 in 110,000</td> <td>G, L, C, M, R</td> <td>Retinopathy, peripheral neuropathy</td> <td>Elevated C16:1–OH–, C16–OH–, C18:1–OH–, C18–OH–</td> </tr> <tr> <td>TFPD</td> <td>Trifunctional protein deficiency</td> <td><em>HADHA, HADHB</em></td> <td>Rare</td> <td>G, L, C, M, R</td> <td>Retinopathy, peripheral neuropathy</td> <td>Elevated C16:1–OH–, C16–OH–, C18:1–OH–, C18–OH–</td> </tr> <tr> <td>CTD</td> <td>Carnitine transporter deficiency</td> <td><em>SLC22A5</em></td> <td>1 in 20,000 to 120,000</td> <td>G, L, C, M, R</td> <td>NBS maternal CTD</td> <td>Low total and free carnitine levels</td> </tr> <tr> <td>CACTD</td> <td>Carnitine-acylcarnitine translocase deficiency</td> <td><em>SLC25A20</em></td> <td>Rare </td> <td>G, L, C</td> <td> </td> <td>Elevated C16–, C16:1–, C18, C18:1–</td> </tr> <tr> <td>CPT1D</td> <td>Carnitine palmitoyltransferase 1A deficiency</td> <td><em>CPT1A</em></td> <td>1 in 500,000</td> <td>G, L</td> <td>Renal tubular acidosis, Arctic variant</td> <td>Elevated total and free plasma carnitine levels</td> </tr> <tr> <td>CPT2D</td> <td>Carnitine palmitoyltransferase 2 deficiency</td> <td><em>CPT2</em></td> <td>Rare </td> <td>G, L, C, M, R</td> <td>Renal cysts, facial dysmorphism</td> <td>Elevated C16–, C16:1–, C18, C18:1–</td> </tr> <tr> <td>MCADD</td> <td>Medium-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADM</em></td> <td> <p>1 in 20,000</p> 1 in 51,000 to 263,000<sup>[1]</sup>​</td> <td>G, L</td> <td> </td> <td>Elevated C6–, C8–, C10–, C10:1–</td> </tr> <tr> <td>MADD</td> <td>Multiple acyl-CoA dehydrogenase deficiency</td> <td><em>ETFA, ETFB, ETFDH</em></td> <td>1 in 15,000 to 2,000,000<sup>[2]</sup> </td> <td>G, L, C, M</td> <td>Renal cysts, congenital malformations, facial dysmorphism, sweaty foot odor</td> <td>Elevated C4–, C5–, C5DC–, C6–, C8–, C10:1–, C12–, C14–, C14:1–, C16–, C16:1–, C18–, C18:1–, C16–OH–, C16:1–OH–, C18–OH–, C18:1–OH–</td> </tr> <tr> <td>SCADD</td> <td>Short-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADS</em></td> <td>1 in 35,000 to 50,000</td> <td> </td> <td>Asymptomatic</td> <td>Elevated C4–</td> </tr> <tr> <td>M/SCHAD</td> <td>Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency</td> <td><em>HADH</em></td> <td>Rare </td> <td> </td> <td>Hyperinsulinism</td> <td>Elevated C4–OH–</td> </tr> </tbody></table></div><div class="graphic_footnotes"><em>ACADVL</em>: acyl-CoA dehydrogenase, very long-chain gene; 

	G: hypoglycemia; 

	L: liver dysfunction; 

	C: cardiomyopathy; 

	M: skeletal myopathy; 

	R: rhabdomyolysis; 

	<em>HADHA:</em> hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit; 

	<em>HADHB</em>: hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit; 

	<em>SLC22A5</em>: solute carrier family 22 member 5 gene; 

	NBS: newborn screening; 

	<em>SLC25A20</em>: solute carrier family 25 member 20 gene; 

	<em>CPT1A</em>: carnitine palmitoyltransferase 1A; 

	<em>CPT2</em>: carnitine palmitoyltransferase 2; 

	<em>ACADM</em>: acyl-CoA dehydrogenase, C-4 to C-12 straight chain; 

	<em>ETFA</em>: electron transfer flavoprotein, alpha subunit; 

	<em>ETFB</em>: electron transfer flavoprotein, beta subunit; 

	<em>ETFDH</em>: electron transfer flavoprotein dehydrogenase; 

	<em>ACADS</em>: acyl-CoA dehydrogenase, C-2 to C-3 short-chain; 

	<em>HADH</em>: 3-hydroxyacyl-CoA dehydrogenase.</div><div class="graphic_reference">References: 

<ol>
<li>Merritt JW II, Chang IJ. Medium-chain acyl-coenzyme A dehydrogenase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, GeneReviews [Internet], University of Washington, Seattle, 2000 (updated 2019).</li>
<li>Linder M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: Experience and recommendations from an expert meeting. J Inherit Metab Dis 2010; 33:521.</li></ol>Adapted from: Sun A, Merritt JW II. Orphan drugs in development for long-chain fatty acid oxidation disorders: Challenges and progress. Orph Drug Res Rev 2015; 5:33.</div><div id="graphicVersion">Graphic 114663 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
